Schubert & Co’s GoodRx Holdings GDRX Stock Holding History

Schubert & Co’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$19	–	613
2023 Q1	$19	Buy	+3	New	+$17	﹤0.01%	1662

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schubert & Co's GDRX Position: Q2 2023 in Review

Schubert & Co sold out of GoodRx Holdings (GDRX) in Q2 2023, closing a stake of 3 shares — an estimated $19 sold.

Schubert & Co first reported a position in GDRX in Q1 2023 and held it in 1 quarter. The position peaked at $19 in Q1 2023. 147 funds tracked by Wall St. Rank hold GDRX as of Q2 2023.

Schubert & Co reported no remaining GoodRx Holdings position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 3 GoodRx Holdings shares in Q2 2023, an estimated $19.
Schubert & Co first reported a position in GoodRx Holdings in Q1 2023 and held it in 1 quarter.
Schubert & Co's GoodRx Holdings position peaked at $19 in Q1 2023.
147 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.